Clinical trial
Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction
NCT00300911 · Baskent University, Other · Completed
Key facts
| NCT number | NCT00300911 |
|---|---|
| Title | Effects of Rosiglitazone on Plasma BNP Levels and Left Ventricular Dysfunction |
| Official title | A Study of PPAR-Gamma Agonist-Rosiglitazone for Determining Cardiac Adverse Effects in Type 2 Diabetic Patients |
| Lead sponsor | Baskent University, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Rosiglitazone(drug), cardiac adverse effects |
| Enrollment | 45 |
| Start date | Dec 1, 2005 |
| First posted | Mar 10, 2006 |
| Last update posted | Mar 10, 2006 |
| Countries | Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: